1414 related articles for article (PubMed ID: 26751469)
1. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
[TBL] [Abstract][Full Text] [Related]
3. Virotherapy: From single agents to combinatorial treatments.
Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
[TBL] [Abstract][Full Text] [Related]
4. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
6. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
[TBL] [Abstract][Full Text] [Related]
7. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
Nguyen TL; Wilson MG; Hiscott J
Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
[TBL] [Abstract][Full Text] [Related]
9. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Nguyên TL; Abdelbary H; Arguello M; Breitbach C; Leveille S; Diallo JS; Yasmeen A; Bismar TA; Kirn D; Falls T; Snoulten VE; Vanderhyden BC; Werier J; Atkins H; Vähä-Koskela MJ; Stojdl DF; Bell JC; Hiscott J
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14981-6. PubMed ID: 18815361
[TBL] [Abstract][Full Text] [Related]
10. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
[TBL] [Abstract][Full Text] [Related]
11. Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.
Alvarez-Breckenridge CA; Choi BD; Suryadevara CM; Chiocca EA
Curr Opin Virol; 2015 Aug; 13():25-32. PubMed ID: 25846988
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
13. Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead.
Li SJ; Sun ZJ
Cancer Lett; 2022 Dec; 550():215937. PubMed ID: 36206966
[TBL] [Abstract][Full Text] [Related]
14. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
15. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
16. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
Oh CM; Chon HJ; Kim C
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086754
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
18. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Nguyen HM; Bommareddy PK; Silk AW; Saha D
Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
[TBL] [Abstract][Full Text] [Related]
19. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Viruses: Therapeutics With an Identity Crisis.
Breitbach CJ; Lichty BD; Bell JC
EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]